The US government, often at odds with environmental legislation, is teaming up with the controversial biotech firm Colossal Biosciences to sequence all genomes of endangered species on the Endangered Species list. Over 2,300 plant and animal populations stand to benefit from this unprecedented effort, which aims to aid in their conservation and potential restoration.
The partnership, a surprising alliance, seeks to preserve tissue samples for future genetic analysis and breeding programs, all under the microscope of Colossal's gene-editing technologies. This move comes as the company continues to draw scrutiny over its ambitious plans to restore extinct species like the dire wolf through selective genetic modifications.
While the bald eagle’s recovery is celebrated, this new initiative promises a broader net to catch species teetering on the brink of extinction. Critics question whether these high-tech methods will truly align with the natural balance or merely serve as a spectacle for future generations.
The project also raises ethical questions about what constitutes a “species” in an era where genetic engineering can blur traditional biological boundaries. As Colossal Biosciences shifts gears from extinct species to endangered ones, the world watches, wondering if this is a step forward or a leap into uncharted territory.







